Statin therapy improvement is a vital necessity for Kazakhstan healthcare

Abstract

Altyn A. Nurpeisova, Raushan Karabayeva, Valeriy V. Benberin, Larisa G. Makalkina

Statins are one of the best studied pharmacological classes. The article discusses various aspects of the safety and effectiveness of statins for the secondary prevention of cardiovascular diseases based on guidelines, systematic reviews, pharmaceutical products monitoring centers and various recommended sources, formed on the basis of the evidence to reduce cases of coronary events. Particular attention is paid to statins, such as simvastatin, atorvastatin, rosuvastatin. The article describes how these parameters should be taken into account by a practitioner. Side effects of these preparations and the possibility of their interaction with other pharmaceutical products are considered to prevent side effects, serious side effects and the lack of effectiveness of statins. The main focus is on statins, since they are considered the most prescribed, highly effective and safe preparations for the secondary cardiovascular prophylaxis.
However, increasing levels of consumption of these drugs and new data on their adverse reactions leave issues of monitoring adverse drug reactions relevant not only in the field of clinical research and testing, but also in the work of a practitioner. Currently, lipid-lowering therapy with statins is considered as a long-term strategy for the secondary prevention of cardiovascular diseases and severe ischemic outcomes: death, apoplectic attack, myocardial infarction. This class of drugs has confirmed a strong effect on reducing mortality from cardiovascular complications with good tolerance and high safety of these drugs. When deciding on the necessity for therapy and the nature of its regimen, target lipoprotein levels in accordance with current recommendations, the risks and benefits ratio for a particular patient should also be considered. When prescribing generic drugs, the same degree of effectiveness and safety is guaranteed only in the case of proven therapeutic equivalence to the original drug.